title: Clinical Management Updates in Mantle Cell Lymphoma.
abstract: Mantle cell lymphoma is an aggressive B-cell non-Hodgkin lymphoma that is often considered incurable. Different clinical and biological biomarkers can be utilized to categorize this lymphoma into various risk levels. Several randomized trials reported in 2015 shed light on the optimal induction therapy. Recent advances include: (1) identification of new pathways to target, (2) novel therapeutics to treat patients with relapsed/refractory disease, and (3) monitoring of minimal residual disease and adoption of a maintenance therapy approach to prevent relapses post induction or post stem cell transplantation. Due to the efforts of translational/clinical research, the overall survival of patients with mantle cell lymphoma has increased and should continue to improve.
authors.forename: Robert
authors.initials: R
authors.lastname: Chen
authors.forename: James
authors.initials: J
authors.lastname: Sanchez
authors.forename: Steven T
authors.initials: ST
authors.lastname: Rosen
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000235:genetics / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D018365:Neoplasm, Residual; D011241:Prednisone / Q000627:therapeutic use; D012008:Recurrence; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone